Lantern Pharma, Inc. (LTRN)
US Market

Lantern Pharma (LTRN) Financial Statements


Lantern Pharma Financial Overview

Lantern Pharma's market cap is currently ―. The company's EPS TTM is $-1.622; its P/E ratio is -3.86; Lantern Pharma is scheduled to report earnings on August 6, 2024, and the estimated EPS forecast is $-0.55. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -4.19M$ -3.16M$ -4.75M$ 4.70M$ 610.61K
EBITDA$ -4.18M$ -3.16M$ -4.74M$ 4.71M$ 608.03K
Net Income Common Stockholders$ -4.19M$ -3.16M$ -4.75M$ 4.70M$ 685.29K
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 41.30M$ 44.93M$ 48.49M$ 52.08M$ 55.74M
Total Assets$ 43.65M$ 47.77M$ 51.43M$ 55.46M$ 58.84M
Total Debt$ 234.47K$ 274.53K$ 313.86K$ 260.22K$ 52.89K
Net Debt$ -41.07M$ -44.65M$ -48.18M$ -51.82M$ -55.68M
Total Liabilities$ 2.74M$ 2.36M$ 3.17M$ 2.93M$ 2.80M
Stockholders Equity$ 40.91M$ 45.41M$ 48.26M$ 52.58M$ 56.04M
Cash Flow-
Free Cash Flow$ -3.39M$ -3.62M$ -3.63M$ -3.73M$ -2.68M
Operating Cash Flow$ -3.39M$ -3.61M$ -3.63M$ -3.72M$ -2.67M
Investing Cash Flow$ 256.18K$ 231.73K$ -457.24K$ -960.88K$ 602.86K
Financing Cash Flow$ -500.00K----
Currency in USD

Lantern Pharma Earnings and Revenue History

Lantern Pharma Debt to Assets

Lantern Pharma Cash Flow

Lantern Pharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis